Trial Profile
A Phase Ib/2 Open-label Study Investigating the Tolerability, Safety, Pharmacokinetic Properties and Efficacy of Oral OKN-007 in Participants With Recurrent High-grade Glioma
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 10 Oct 2022
Price :
$35
*
At a glance
- Drugs Disufenton (Primary)
- Indications Astrocytoma; Glioblastoma; Glioma; Oligodendroglioma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Oblato
- 05 Oct 2022 Status changed from not yet recruiting to withdrawn prior to enrolment. Reason the study was stopped: Planned to execute the new Oral OKN-007 clinical trial with modified study plan soon. This Study not proceeding and sites never opened.
- 26 Sep 2021 Planned End Date changed from 1 Apr 2024 to 1 Aug 2025.
- 26 Sep 2021 Planned primary completion date changed from 1 Feb 2024 to 1 Apr 2025.